AGENUS INC Gain (Loss) on Disposition of Assets
AGENUS INC (AGEN) reported Gain (Loss) on Disposition of Assets of $0 for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Income Statement › Other Income
us-gaap:GainLossOnDispositionOfAssets1 · last filed 2026-08-07
- AGENUS INC gain (loss) on disposition of assets for the quarter ending 2026-06-30 was $0.00.
- AGENUS INC gain (loss) on disposition of assets for the quarter ending 2026-03-31 was $40.38M.
- AGENUS INC gain (loss) on disposition of assets for the quarter ending 2025-12-31 was -$1.00K.
- AGENUS INC gain (loss) on disposition of assets for the quarter ending 2025-09-30 was -$936.00K.
- AGENUS INC gain (loss) on disposition of assets for fiscal 2025 was -$937.00K.
- AGENUS INC gain (loss) on disposition of assets for fiscal 2024 was -$1.15M, a 181.89% decline from fiscal 2023.
- AGENUS INC gain (loss) on disposition of assets for fiscal 2023 was $1.41M, a 91.31% decline from fiscal 2022.
- AGENUS INC gain (loss) on disposition of assets for fiscal 2022 was $16.20M, a 390.64% increase from fiscal 2021.
| Period end | Gain (Loss) on Disposition of Assets 3 month | Gain (Loss) on Disposition of Assets 6 month | Gain (Loss) on Disposition of Assets 6 month as first filed | Gain (Loss) on Disposition of Assets 9 month | Gain (Loss) on Disposition of Assets 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-07 | $40.38M 10-Q · filed 2026-08-07 | $40.38M derived: sum of 3 quarters · filed 2026-08-07 | $39.44M derived: sum of 4 quarters · filed 2026-08-07 | |
| 2026-03-31 | $40.38M 10-Q · filed 2026-05-11 | $40.38M derived: sum of 2 quarters · filed 2026-05-11 | $39.44M derived: sum of 3 quarters · filed 2026-05-11 | $39.44M derived: sum of 4 quarters · filed 2026-08-07 | |
| 2025-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$937.00K derived: sum of 2 quarters · filed 2026-03-16 | -$937.00K derived: sum of 3 quarters · filed 2026-08-07 | -$937.00K 10-K · filed 2026-03-16 | |
| 2025-09-30 | -$936.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$936.00K derived: sum of 2 quarters · filed 2026-08-07 | -$936.00K 10-Q · filed 2025-11-10 | -$2.07M derived: sum of 4 quarters · filed 2026-08-07 | |
| 2025-06-30 | $0.00 10-Q · filed 2026-08-07 | $0.00 10-Q · filed 2026-08-07 | -$929.00K 10-Q · filed 2025-08-11 | -$1.14M derived: sum of 3 quarters · filed 2026-08-07 | -$1.14M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-11 | -$1.14M derived: sum of 2 quarters · filed 2026-05-11 | -$1.14M derived: sum of 3 quarters · filed 2026-05-11 | -$1.14M derived: sum of 4 quarters · filed 2026-05-11 | |
| 2024-12-31 | -$1.14M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$1.14M derived: sum of 2 quarters · filed 2026-03-16 | -$1.14M derived: sum of 3 quarters · filed 2026-03-16 | -$1.15M 10-K · filed 2026-03-16 | |
| 2024-09-30 | -$9.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$9.00K derived: sum of 2 quarters · filed 2025-11-10 | -$18.00K 10-Q · filed 2025-11-10 | $1.44M derived: sum of 4 quarters · filed 2026-03-16 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | -$9.00K 10-Q · filed 2025-08-11 | $1.45M derived: sum of 3 quarters · filed 2026-03-16 | $1.45M derived: sum of 4 quarters · filed 2026-03-16 | |
| 2024-03-31 | -$9.00K 10-Q · filed 2024-05-07 | $1.45M derived: sum of 2 quarters · filed 2026-03-16 | $1.45M derived: sum of 3 quarters · filed 2026-03-16 | $1.42M derived: sum of 4 quarters · filed 2026-03-16 | |
| 2023-12-31 | $1.46M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $1.46M derived: sum of 2 quarters · filed 2026-03-16 | $1.43M derived: sum of 3 quarters · filed 2026-03-16 | $1.41M 10-K · filed 2026-03-16 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$28.00K derived: sum of 2 quarters · filed 2024-11-12 | -$49.00K 10-Q · filed 2024-11-12 | $9.55M derived: sum of 4 quarters · filed 2025-03-17 | |
| 2023-06-30 | -$28.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$49.00K 10-Q · filed 2024-08-08 | $9.55M derived: sum of 3 quarters · filed 2025-03-17 | $9.55M derived: sum of 4 quarters · filed 2025-03-17 | |
| 2023-03-31 | -$21.00K 10-Q · filed 2024-05-07 | $9.57M derived: sum of 2 quarters · filed 2025-03-17 | $9.57M derived: sum of 3 quarters · filed 2025-03-17 | $16.18M derived: sum of 4 quarters · filed 2025-03-17 | |
| 2022-12-31 | $9.60M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $9.60M derived: sum of 2 quarters · filed 2025-03-17 | $16.20M derived: sum of 3 quarters · filed 2025-03-17 | $16.20M 10-K · filed 2025-03-17 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $6.60M derived: sum of 2 quarters · filed 2023-11-09 | $6.60M 10-Q · filed 2023-11-09 | $9.98M derived: sum of 4 quarters · filed 2024-03-14 | |
| 2022-06-30 | $6.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $6.60M 10-Q · filed 2023-08-08 | $9.98M derived: sum of 3 quarters · filed 2024-03-14 | ||
| 2022-03-31 | -$2.00K 10-Q · filed 2023-05-09 | $3.38M derived: sum of 2 quarters · filed 2024-03-14 | |||
| 2021-12-31 | $3.38M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $3.30M 10-K · filed 2024-03-14 | |||
| 2021-09-30 | -$83.00K 10-Q · filed 2022-11-08 | ||||
| 2020-12-31 | -$184.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | -$198.00K 10-K · filed 2023-03-16 | |||
| 2020-09-30 | -$14.00K 10-Q · filed 2021-11-09 | ||||
| 2019-12-31 | -$58.00K 10-K · filed 2022-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |